Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease in Women with Rheumatoid Arthritis

Table 3

Logistic regression analysis performed to assess the risk factors associated with the RA-ILD.

Criterion predictor	Method Enter			Method Forward Stepwise
	OR	95% CI		OR	95% CI
Age, years	1.01	0.89–1.15	0.86	Not in the model	—	—
Disease duration >5 years	10.79	0.68–170.99	0.09	Not in the model	—	—
Smoke exposure	1.19	0.20–7.13	0.84	Not in the model	—	—
DAS28	0.29	0.03–1.48	0.12	Not in the model	—	—
HAQ-Di	1.17	0.12–11.16	0.89	Not in the model	—	—
ESR, mm/h	1.18	0.98–1.42	0.08	Not in the model
Anti-CCP2 titers	1.05	1.01–1.10	0.01	1.06	1.02–1.10	0.003
+Rheumatoid factor	26.84	2.31–311.58	0.009	28.58	3.31–246.95	0.002
MTX treatment duration	1.60	1.00–2.56	0.05	Not in the model	—	—

DAS28: disease activity score; HAQ-Di: Health Assessment Questionnaire-Disability Index; ESR: erythrocyte sedimentation rate; MTX: methotrexate; anti-CCP2 titers: anti-cyclic citrullinated peptide antibodies titers (second generation); OR: odds ratios; 95% CI: 95% confidence interval. Variables were adjusted using logistic regression analysis. Dependent variable: presence or absence of interstitial lung disease. Covariates: age (quantitative), disease duration >5 years (qualitative), smoke exposure (qualitative), DAS28 (quantitative), HAQ-Di (quantitative), anti-CCP2 titers (quantitative), +rheumatoid factor (qualitative), and MTX duration in treatment (quantitative).